Group 1 - The core viewpoint of the articles highlights the advancements made by Aipeng Medical in the commercialization of brain-computer interface technology, particularly in the treatment of refractory insomnia and ADHD [1][4]. - Aipeng Medical has developed a comprehensive system for managing refractory insomnia, which includes both hardware and software components, addressing clinical needs through digital interactions between patients and healthcare providers [1][2]. - The refractory insomnia treatment system integrates various functionalities such as assessment, drug titration, monitoring of sedation depth, and life sign tracking, creating a complete treatment loop from hospitalization to long-term recovery [1][2]. Group 2 - Refractory insomnia, defined as chronic insomnia lasting over two years and resistant to multiple treatments, represents a significant market opportunity, accounting for 20% to 30% of insomnia cases [2]. - The National Health Commission of China has recognized the potential for anesthesia departments to explore treatments for sleep disorders, indicating a supportive regulatory environment for such innovations [2]. - The collaboration between Aipeng Medical and Sun Yat-sen University Sun Yat-sen Memorial Hospital showcases the integration of neuro-regulation and pharmacological treatments, providing a model for other medical institutions [3][4]. Group 3 - Aipeng Medical has initiated a joint laboratory with Fudan University Children's Hospital to focus on ADHD treatment, emphasizing the importance of brain-computer interface technology in developing innovative therapeutic solutions [4]. - The company is actively pursuing clinical applications of its brain-computer interface technology across various mental health conditions, positioning itself as a leader in this emerging field [4].